Ocugen wins FDA RMAT designation for OCU410 targeting 2M GA patients

A one-time gene therapy for geographic atrophy just got a regulatory shortcut that could cut years off its path to market, challenging a treatment paradigm built on chronic injections.

Ocugen Inc. said the US Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to OCU410, an investigational gene therapy for geographic atrophy secondary to dry age-related macular degeneration that affects an estimated 2 million to 3 million people in the US and Europe.

"RMAT designation for OCU410 is a significant accomplishment that recognizes both the potential of our 'one treatment for life' novel gene therapy platform and the substantial unmet medical need for geographic atrophy," Dr. Shankar Musunuri, chairman, chief executive officer and co-founder of Ocugen, said.

The RMAT designation was supported by Phase 2 data showing clinically meaningful efficacy and no serious adverse events related to the drug. Ocugen reached alignment with the FDA on the Phase 3 registrational trial design in early July, with study initiation expected in the third quarter of 2026 and a Biologics License Application filing anticipated in 2028. The company also received Advanced Therapy Medicinal Product classification from the European Medicines Agency.

Why RMAT matters for OCU410's commercial prospects

RMAT designation grants all the benefits of the FDA's Fast Track and Breakthrough Therapy programs, including increased agency interactions, rolling BLA review, and the potential for accelerated approval and Priority Review. For Ocugen, a company with no approved products, the designation reduces both development risk and time to market.

The current standard of care for geographic atrophy requires chronic intravitreal injections — a burden that limits patient adherence and drives demand for durable alternatives. Apellis Pharmaceuticals' Syfovre and Iveric Bio's Izervay, both approved in 2023, generated combined sales of about $800 million in 2025 but require injections every 25 to 60 days. OCU410, delivered as a single subretinal injection, aims to eliminate the need for repeat dosing entirely.

How OCU410's mechanism differs from approved therapies

OCU410 uses an AAV5 vector to deliver the RORA gene, a nuclear receptor that regulates oxidative stress response, complement regulation, inflammation and lipid metabolism — four pathways implicated in geographic atrophy progression. This modifier gene therapy approach contrasts with approved complement inhibitors that target a single pathway. Ocugen's platform is designed to restore balance across multiple gene networks rather than correcting a single mutation, a strategy the company is also applying to retinitis pigmentosa and Stargardt disease.

Dry AMD affects about 10 million Americans and more than 266 million people worldwide, with 85 percent to 90 percent of cases classified as the dry form. Geographic atrophy, the advanced stage, leads to irreversible central vision loss and is a leading cause of blindness in older adults.

What this means for Ocugen's path to market

The RMAT designation could reduce trial duration and regulatory costs by enabling smaller, faster studies under the accelerated approval pathway. A BLA filing in 2028, if achieved, would position OCU410 to enter a market that analysts project could exceed $3 billion annually in the US alone as the population ages.

This article is for informational purposes only and does not constitute investment advice.